{"id":12650,"date":"2021-09-21T15:07:04","date_gmt":"2021-09-21T19:07:04","guid":{"rendered":"https:\/\/ccna-ccnv.ca\/?post_type=ccna_publication&#038;p=12650"},"modified":"2025-03-26T16:10:48","modified_gmt":"2025-03-26T20:10:48","slug":"apolipoprotein-b-is-a-novel-marker-for-early-tau-pathology-in-alzheimers-disease","status":"publish","type":"ccna_publication","link":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/apolipoprotein-b-is-a-novel-marker-for-early-tau-pathology-in-alzheimers-disease\/","title":{"rendered":"Apolipoprotein B is a novel marker for early tau pathology in Alzheimer&rsquo;s disease"},"content":{"rendered":"<h2>Abstract<\/h2>\n<p><strong class=\"sub-title\">Introduction:\u00a0<\/strong>We examine the role of brain apolipoprotein B (apoB) as a putative marker of early tau pathology and cognitive decline.<\/p>\n<p><strong class=\"sub-title\">Methods:\u00a0<\/strong>Cerebrospinal fluid (CSF) samples from cognitively normal and Alzheimer&rsquo;s disease (AD) participants were collected to measure protein levels of apoB and AD biomarkers amyloid beta (A\u03b2), t-tau and p-tau, as well as synaptic markers GAP43, SYNAPTOTAGMIN-1, synaptosome associated protein 25 (SNAP-25), and NEUROGRANIN. CSF apoB levels were contrasted with positron emission tomography (PET) scan measures of A\u03b2 (18F-NAV4694) and Tau (flortaucipir) along with cognitive assessment alterations over 6 to 8 years.<\/p>\n<p><strong class=\"sub-title\">Results:\u00a0<\/strong>CSF apoB levels were elevated in AD participants and correlated with t-tau, p-tau, and the four synaptic markers in pre-symptomatic individuals. In the latter, CSF apoB levels correlated with PET flortaucipir-binding in entorhinal, parahippocampal, and fusiform regions. Baseline CSF apoB levels were associated with longitudinal visuospatial cognitive decline.<\/p>\n<p><strong class=\"sub-title\">Discussion:\u00a0<\/strong>CSF apoB markedly associates with early tau dysregulation in asymptomatic subjects and identifies at-risk individuals predisposed to develop visuospatial cognitive decline over time.<\/p>\n","protected":false},"author":14,"featured_media":0,"template":"","meta":{"_acf_changed":false},"studies-relation":[51],"class_list":["post-12650","ccna_publication","type-ccna_publication","status-publish","hentry","studies-relation-compass-nd-fr"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Apolipoprotein B is a novel marker for early tau pathology in Alzheimer&#039;s disease - CCNA - CCNV<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/apolipoprotein-b-is-a-novel-marker-for-early-tau-pathology-in-alzheimers-disease\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Apolipoprotein B is a novel marker for early tau pathology in Alzheimer&#039;s disease - CCNA - CCNV\" \/>\n<meta property=\"og:description\" content=\"Abstract Introduction:\u00a0We examine the role of brain apolipoprotein B (apoB) ...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/apolipoprotein-b-is-a-novel-marker-for-early-tau-pathology-in-alzheimers-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"CCNA - CCNV\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-26T20:10:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/CCNA.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/apolipoprotein-b-is-a-novel-marker-for-early-tau-pathology-in-alzheimers-disease\/\",\"url\":\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/apolipoprotein-b-is-a-novel-marker-for-early-tau-pathology-in-alzheimers-disease\/\",\"name\":\"Apolipoprotein B is a novel marker for early tau pathology in Alzheimer's disease - CCNA - CCNV\",\"isPartOf\":{\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#website\"},\"datePublished\":\"2021-09-21T19:07:04+00:00\",\"dateModified\":\"2025-03-26T20:10:48+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/apolipoprotein-b-is-a-novel-marker-for-early-tau-pathology-in-alzheimers-disease\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/apolipoprotein-b-is-a-novel-marker-for-early-tau-pathology-in-alzheimers-disease\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/apolipoprotein-b-is-a-novel-marker-for-early-tau-pathology-in-alzheimers-disease\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ccna-ccnv.ca\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Apolipoprotein B is a novel marker for early tau pathology in Alzheimer&#8217;s disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#website\",\"url\":\"https:\/\/ccna-ccnv.ca\/fr\/\",\"name\":\"Canadian Consortium on Neurodegeneration in Aging\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#organization\"},\"alternateName\":\"CCNA - CCNV\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ccna-ccnv.ca\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#organization\",\"name\":\"Canadian Consortium on Neurodegeneration in Aging\",\"alternateName\":\"CCNA - CCNV\",\"url\":\"https:\/\/ccna-ccnv.ca\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/ccna-logo-on-white-background.jpg\",\"contentUrl\":\"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/ccna-logo-on-white-background.jpg\",\"width\":696,\"height\":696,\"caption\":\"Canadian Consortium on Neurodegeneration in Aging\"},\"image\":{\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Apolipoprotein B is a novel marker for early tau pathology in Alzheimer's disease - CCNA - CCNV","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/apolipoprotein-b-is-a-novel-marker-for-early-tau-pathology-in-alzheimers-disease\/","og_locale":"fr_CA","og_type":"article","og_title":"Apolipoprotein B is a novel marker for early tau pathology in Alzheimer's disease - CCNA - CCNV","og_description":"Abstract Introduction:\u00a0We examine the role of brain apolipoprotein B (apoB) ...","og_url":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/apolipoprotein-b-is-a-novel-marker-for-early-tau-pathology-in-alzheimers-disease\/","og_site_name":"CCNA - CCNV","article_modified_time":"2025-03-26T20:10:48+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/CCNA.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/apolipoprotein-b-is-a-novel-marker-for-early-tau-pathology-in-alzheimers-disease\/","url":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/apolipoprotein-b-is-a-novel-marker-for-early-tau-pathology-in-alzheimers-disease\/","name":"Apolipoprotein B is a novel marker for early tau pathology in Alzheimer's disease - CCNA - CCNV","isPartOf":{"@id":"https:\/\/ccna-ccnv.ca\/fr\/#website"},"datePublished":"2021-09-21T19:07:04+00:00","dateModified":"2025-03-26T20:10:48+00:00","breadcrumb":{"@id":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/apolipoprotein-b-is-a-novel-marker-for-early-tau-pathology-in-alzheimers-disease\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/apolipoprotein-b-is-a-novel-marker-for-early-tau-pathology-in-alzheimers-disease\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/apolipoprotein-b-is-a-novel-marker-for-early-tau-pathology-in-alzheimers-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ccna-ccnv.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Apolipoprotein B is a novel marker for early tau pathology in Alzheimer&#8217;s disease"}]},{"@type":"WebSite","@id":"https:\/\/ccna-ccnv.ca\/fr\/#website","url":"https:\/\/ccna-ccnv.ca\/fr\/","name":"Canadian Consortium on Neurodegeneration in Aging","description":"","publisher":{"@id":"https:\/\/ccna-ccnv.ca\/fr\/#organization"},"alternateName":"CCNA - CCNV","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ccna-ccnv.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/ccna-ccnv.ca\/fr\/#organization","name":"Canadian Consortium on Neurodegeneration in Aging","alternateName":"CCNA - CCNV","url":"https:\/\/ccna-ccnv.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/ccna-ccnv.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/ccna-logo-on-white-background.jpg","contentUrl":"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/ccna-logo-on-white-background.jpg","width":696,"height":696,"caption":"Canadian Consortium on Neurodegeneration in Aging"},"image":{"@id":"https:\/\/ccna-ccnv.ca\/fr\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/ccna_publication\/12650","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/ccna_publication"}],"about":[{"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/types\/ccna_publication"}],"author":[{"embeddable":true,"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/users\/14"}],"wp:attachment":[{"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/media?parent=12650"}],"wp:term":[{"taxonomy":"studies-relation","embeddable":true,"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/studies-relation?post=12650"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}